Riskpilot← Back to searchSign inGet full accessBRAINSYMPH AS
ASActiveOrg 924345519Ringbakken 2, 3132 HusøysundResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20203 employeesbrainsymph.com
Revenue 2024
NOK 3,4M
+65% vs 2023
EBITDA margin
19.5%
+44% vs 2023
Equity ratio
78.3%
Financial strength
Net profit 2024
NOK 500K
+16% vs 2023
| Revenue | NOK 3,4M | +65% |
| EBITDA | NOK 656K | +44% |
| Net profit | NOK 500K | +16% |
| Total assets | NOK 1,7M | +50% |
| Equity | NOK 1,3M | +61% |
| Employees | 3 | — |
Legal name
BRAINSYMPH AS
Org number
924345519
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
6. januar 2020
Share capital
NOK 30 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Medisinsk diagnostisk teknologiutvikling og deltagelse i andre selskaper.
Address
Ringbakken 2, 3132 Husøysund
Phone
+4795046333
Email
post@brainsymph.com
Website
brainsymph.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 51 | 1 228 | 1 355 | 2 040 | 3 362 |
| Staff expenses | −0 | −780 | −1 151 | −1 355 | −907 |
| EBITDA | 18 | 24 | 21 | 455 | 656 |
| Depreciation & amort. | −0 | −10 | −30 | −31 | −25 |
| EBIT | 18 | 14 | −9 | 424 | 631 |
| Net financials | 0 | 1 | −7 | 5 | 2 |
| Profit before tax | 18 | 15 | −16 | 429 | 633 |
| Tax | 1 | 3 | −2 | −1 | 133 |
| Net profit | 17 | 12 | −14 | 430 | 500 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 110 | 2 323 | 2 270 | 1 125 | 1 693 |
| Equity | 35 | 47 | 33 | 826 | 1 326 |
| Long-term debt | 0 | 4 | 1 | 0 | 0 |
| Short-term debt | 74 | 2 273 | 2 236 | 300 | 367 |
| Total debt | 75 | 2 276 | 2 237 | 300 | 367 |
EBITDA margin
19.5%
This company
15.8%
Market median
+23% vs market
20202024
Equity ratio
78.3%
This company
38.2%
Market median
+105% vs market
20202024
Return on equity
37.7%
This company
18.4%
Market median
+105% vs market
20202024
Net profit margin
14.9%
This company
8.1%
Market median
+84% vs market
20202024
Asset turnover
1.99×
This company
1.12×
Market median
+78% vs market
20202024
Debt / equity
0.28×
This company
0.62×
Market median
+55% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LJ Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
AR Chief Executive Officer | Chief Executive Officer | 2026 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Global Psychiatry Partners As | Company | 50.0% | 50.0% | 2024 |
Min Fullmakt As | Company | 34.0% | 34.0% | 2024 |
| Individual | 10.0% | 10.0% | 2024 | |
| Individual | 6.0% | 6.0% | 2022 | |
| Individual | 6.0% | 6.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BRAINSYMPH AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lillian Juliane Fjeld | Chief Executive Officer | 0 companies |
| Arnt Röch-Pettersen | Chief Executive Officer | 0 companies |
| Christoffer Hatlestad-Hall | Board of Directors | 0 companies |
| Ira Ronit Juleica Hebold Haraldsen | Chairman | 0 companies |
| Theodor Remman | Board of Directors | 0 companies |